<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7064180/results/search/test_trace/results.xml">
  <result pre="Background Directly acting antivirals (DAA) against hepatitis C virus (HCV)" exact="infection" post="have facilitated sustained virologic response (SVR) rates &amp;gt;90% in"/>
  <result pre="&amp;gt;90% in clinical studies. Yet, real life data regarding DAA" exact="treatment" post="in people who inject drugs (PWIDs) are scarce. We"/>
  <result pre="at high risk for non-adherence to DAA therapy received HCV" exact="treatment" post="together with their OST under the supervision of medical"/>
  <result pre="drugs (PWIDs) represent a relevant at-risk population for hepatitis C" exact="infection" post="and transmission, yet treatment efficacy is often limited by"/>
  <result pre="relevant at-risk population for hepatitis C infection and transmission, yet" exact="treatment" post="efficacy is often limited by poor adherence to clinical"/>
  <result pre="achieve excellent HCV cure rates. Introduction Hepatitis C virus (HCV)" exact="infection" post="is a leading cause for cirrhosis, liver-related complications, hepatocellular"/>
  <result pre="complications, hepatocellular carcinoma (HCC), liver transplantation and death worldwide. HCV" exact="treatment" post="at an early stage of the disease can prevent"/>
  <result pre="drug tolerability profile in nearly all patients[3–8]. The latest pangenotypic" exact="treatment" post="regimens induce excellent SVR (sustained virologic response) rates independent"/>
  <result pre="to pangenotypic DAA therapy is still limited by the high" exact="treatment" post="costs[11]. The 2015 Agenda for Sustainable Development committed to"/>
  <result pre="sets per patient per year. Furthermore, an increase in HCV" exact="diagnosis" post="from &amp;lt;5% (2015) to 90% (2030) and in treatment"/>
  <result pre="HCV diagnosis from &amp;lt;5% (2015) to 90% (2030) and in" exact="treatment" post="uptake from &amp;lt;1% (2015) to 80% of all eligible"/>
  <result pre="comorbidities as well as patients with a history of previous" exact="treatment" post="failure[19–27]. Yet, real world data on G/P are still"/>
  <result pre="hepatitis C, 18 years of age or older, who started" exact="treatment" post="with G/P at our center (comprising a tertiary care"/>
  <result pre="and December 2018 were included in this analysis. Setting of" exact="treatment" post="In Vienna there is a large population of about"/>
  <result pre="Wilhelminen Hospital Vienna and the Ambulatorium Suchthilfe Wien–a low-threshold drug" exact="treatment" post="facility in Vienna. A second outpatient hepatitis clinic was"/>
  <result pre="and all equipment for pretreatment evaluation of patients including laboratory" exact="tests" post="and Fibroscan® was available. This low-threshold facility combines HCV"/>
  <result pre="tests and Fibroscan® was available. This low-threshold facility combines HCV" exact="screening" post="and treatment for PWIDs by offering an integrative management"/>
  <result pre="Fibroscan® was available. This low-threshold facility combines HCV screening and" exact="treatment" post="for PWIDs by offering an integrative management in a"/>
  <result pre="therapy every month and were only seen for routine laboratory" exact="tests" post="at the outpatient clinic (&quot;standard setting therapy group&quot;). The"/>
  <result pre="clinic (&quot;standard setting therapy group&quot;). The assignment to the different" exact="treatment" post="groups (SS vs. DOT) was made by an interdisciplinary"/>
  <result pre="the entire team and the assignment to either of the" exact="treatment" post="groups was made following a discussion among all team"/>
  <result pre="of HCV therapy as reported by the patient. No additional" exact="screening" post="was performed in order to assess recent drug use."/>
  <result pre="patients[34]. If a patient missed ingestion of the drugs, the" exact="treatment" post="period was prolonged for one day; i.e. our aim"/>
  <result pre="HCV-RNA level &amp;lt;15 IU/ml 12 weeks after the end of" exact="treatment" post="(SVR12). SVR12 rates were calculated for the intention-to-treat (ITT)"/>
  <result pre="the percentage of men was slightly higher, as was the" exact="prevalence" post="of GT1a. Most PWIDs included in the DOT-group were"/>
  <result pre="after end of therapy. b 16 weeks after end of" exact="treatment" post="for reasons not related to therapy. 10.1371/journal.pone.0229239.t002Table 2 Socioeconomic"/>
  <result pre="One patient was lost to follow-up (FU) after end of" exact="treatment" post="response was documented, and one treatment-naïve patient with GT3"/>
  <result pre="in the SS (Fig 2A–2C). Fig 2 SVR12 rates after" exact="treatment" post="with G/P according to mITT. Abbreviations: SVR, sustained virologic"/>
  <result pre="weeks after end of therapy for reasons not related to" exact="treatment" post="after showing a negative HCV-RNA PCR result three weeks"/>
  <result pre="≥9.5 kPa according to transient elastography. C—Patients with HCV GT3" exact="infection" post="(n = 54/56). In the DOT-group SVR12 was achieved"/>
  <result pre="weeks after end of therapy for reasons not related to" exact="treatment" post="after showing a negative HCV-RNA PCR result three weeks"/>
  <result pre="12 weeks after cessation of therapy. One patient with GT3" exact="infection" post="and fibrosis stage F0/F1 who was treated for eight"/>
  <result pre="due to very poor compliance to clinical visits HCV resistance" exact="testing" post="could not be performed. All four patients without SVR12"/>
  <result pre="scheduled dates were missed by the patients. No patient discontinued" exact="treatment" post="because of adverse events or lack of compliance. Serious"/>
  <result pre="71 weeks after end of therapy. The presumed mode of" exact="infection" post="was needle sharing with a friend. Yet, 28 patients"/>
  <result pre="cannot exclude that some reinfections were missed. Discussion In Austria," exact="treatment" post="of hepatitis C is only performed at a limited"/>
  <result pre="HCV-infected patients have been successfully treated in Vienna[18]. Yet, HCV" exact="prevalence" post="among PWIDs remains high. Especially PWIDs with ongoing IDU"/>
  <result pre="low-threshold facilities would further increase DAA adherence and improve HCV" exact="treatment" post="outcomes in PWIDs on stable OST with or without"/>
  <result pre="without ongoing IDU. The Ambulatorium Suchthilfe Wien, a low-threshold drug" exact="treatment" post="facility in Vienna, offers integrative management combining HCV screening"/>
  <result pre="drug treatment facility in Vienna, offers integrative management combining HCV" exact="screening" post="and therapy for PWIDs by providing hepatological, psychiatric and"/>
  <result pre="high SVR rates that did not relevantly deviate from the" exact="treatment" post="outcomes in patients without a history of IDU go"/>
  <result pre="literature and support the recommendations of broad access to HCV" exact="treatment" post="[35,36]. From our results we conclude that directly observed"/>
  <result pre="in Austria. In accordance with previous studies, SVR rates after" exact="treatment" post="with G/P were excellent and no serious adverse events"/>
  <result pre="of PWIDs at our low-threshold facilities in Vienna that offer" exact="counseling" post="and syringe exchange services along with medical treatment for"/>
  <result pre="that offer counseling and syringe exchange services along with medical" exact="treatment" post="for PWIDs[39]. We present results of a monocenter study"/>
  <result pre="SS of HCV care. The specific characterization of the real-world" exact="treatment" post="outcome of G/P in difficult-to-treat PWIDs with and without"/>
  <result pre="treat patients, we are planning to introduce a peer-based HCV" exact="screening" post="and treatment program for PWIDs in Vienna. The project"/>
  <result pre="we are planning to introduce a peer-based HCV screening and" exact="treatment" post="program for PWIDs in Vienna. The project shall focus"/>
  <result pre="have successfully been cured from HCV or are currently on" exact="treatment" post="bringing their friends along to the diagnostic facility and"/>
  <result pre="the diagnostic facility and thereby linking HCV infected PWIDs to" exact="treatment" post="who would otherwise not attend a medical facility. To"/>
  <result pre="Health Organization References References 1collab: Polaris Observatory HCV Collaborators. Global" exact="prevalence" post="and genotype distribution of hepatitis C virus infection in"/>
  <result pre="Collaborators. Global prevalence and genotype distribution of hepatitis C virus" exact="infection" post="in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76."/>
  <result pre="20183;30(3):291–5. 10.1097/MEG.000000000000102729120906 8MandorferM, SchwablP, SteinerS, ScheinerB, ChromyD, BucsicsT, et al.Interferon-free" exact="treatment" post="with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of"/>
  <result pre="2015. https://www.un.org/ga/search/view_doc.asp?symbol=A/RES/70/1&amp;amp;Lang=E%20(accessed%202%20April%202016) 14collab: European Union HCV Collaborators. Hepatitis C virus" exact="prevalence" post="and level of intervention required to achieve the WHO"/>
  <result pre="hepatitis C virus genotype 1, 2, 4, 5, or 6" exact="infection" post="in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label,"/>
  <result pre="C virus genotype 1 or 4 and past direct-acting antiviral" exact="treatment" post="failure. Hepatol Baltim Md. 2018;67(4):1253–60. 23WylesD, PoordadF, WangS, AlricL,"/>
  <result pre="hepatitis C virus genotype 3 patients with cirrhosis and/or prior" exact="treatment" post="experience: A partially randomized phase 3 clinical trial. Hepatol"/>
  <result pre="AsatryanA, TrinhR, et al.Safety and efficacy of glecaprevir/pibrentasvir for the" exact="treatment" post="of chronic hepatitis C in patients aged 65 years"/>
  <result pre="ScheinerB, StrasslR, MayerF, et al.Non-invasive liver fibrosis assessment and HCV" exact="treatment" post="initiation within a systematic screening program in HIV/HCV coinfected"/>
  <result pre="liver fibrosis assessment and HCV treatment initiation within a systematic" exact="screening" post="program in HIV/HCV coinfected patients. Wien Klin Wochenschr. 20182;130(3–4):105–14."/>
  <result pre="Am. 2019912; 36HajarizadehB, CunninghamEB, ReidH, LawM, DoreGJ, GrebelyJ. Direct-acting antiviral" exact="treatment" post="for hepatitis C among people who use or inject"/>
  <result pre="patients with chronic hepatitis C virus genotype 5 or 6" exact="infection" post="(ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol"/>
 </snippets>
</snippetsTree>
